PTX-022 in the Treatment of Microcystic Lymphatic Malformations
Contact
Description
The purpose of this study is to see if a new investigational topical (applied to the skin) formulation of sirolimus, PTX-022 (the study drug), is safe and effective in treating participants with microcystic Lymphatic Malformations.
Eligibility and criteria
IRB Number:
23-021775
Eligible age range:
Clinical trial phase:
Phase III
Official title:
What to expect
Related specialties

We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.